To study the use of atropine(0.01%)eye drops in halting progression of myopia
- Conditions
- Health Condition 1: H521- Myopia
- Registration Number
- CTRI/2020/04/024464
- Lead Sponsor
- Dr Arvind Kumar Morya
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
1.All patients with age group 05 to 23 years.
2.Gender male and female
3.Best corrected visual acuity should be 6/6 (20/20; LogMAR 0.0) or better in both eyes
4.Spherical equivalent should be equal to or more than -0.25Diopter
5.Both spherical and or cylindrical refraction would be included. Refraction would be based on cycloplegic refraction and subjective acceptance
6.Patients/legal guardian should be willing to use the eye drops on regular compliant basis.
7.Patients/legal guardian should be able to understand and sign an informed consent.
1.History of ocular inflammation or trauma or treatment of refractive error (medical or surgical)
2.Any ocular comorbidity limiting visual assessment, visual improvement.
3.Any type of amblyopia in one or both eyes.
4.Patient lost to follow up within 1 year of the study or not compliant with the treatment advised
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary: <br/ ><br>To compare the the efficacy and safety of atropine 0.01% eye drops in controlling progression of myopia. <br/ ><br>Secondary : <br/ ><br>To evaluate the systemic and ocular side effects of atropine eye drops 0.01% in myopic patients. <br/ ><br> <br/ ><br> <br/ ><br>Timepoint: Change in spherical equivalent at the end of 2 years. <br/ ><br>
- Secondary Outcome Measures
Name Time Method To evaluate the efficacy of atropine 0.01% eye drops in arresting the progression of myopiaTimepoint: To evaluate the efficacy of atropine 0.01% eye drops in arresting the progression of myopia at 2 year of therapy